bimekizumab vs sonelokimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-17A/F · full Psoriasis pipeline
bimekizumab · Bimzelx
Marketed by UCB
NCT03370133 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).
Next expected readout: March 2027 · NCT06506916 (registry estimate)
Reported efficacy
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16; Percentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2% (met)
Result source: NCT03412747
sonelokimab
Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA
NCT03384745 · Phase 2 · completed
This was a well-powered, randomized, blinded, placebo-controlled trial using a validated skin-clearance measure as its primary endpoint, and every sonelokimab dose group achieved a substantially and statistically significantly higher clear/almost-clear skin rate than placebo at week 12.
Reported efficacy
Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 (Week 12, as compared to Week 0 (baseline)): Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo. (met)
Result source: NCT03384745
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | bimekizumab | sonelokimab |
|---|---|---|
| PASI 75 | 76.9% vs 2.4%+74.5 vs placeboNCT0337013310 other results
| 84.9% vs 90.6%vs SecukinumabNCT033847453 other results
|
| PASI 90 | 85% vs 4.8%+80.2 vs placeboNCT0337013348 other results
| 69.8% vs 64.2%vs SecukinumabNCT033847453 other results
|
| PASI 100 | 61.7% vs 48.9%vs SecukinumabNCT0353688410 other results
| 37.7% vs 28.3%vs SecukinumabNCT033847453 other results
|
| sPGA 0/1 | 84.1% vs 4.8%+79.3 vs placeboNCT033701331 other result
| —Not reported |
| DLQI, change | —Trial running · NCT06506916 | —Not reported |
PASI 75
- bimekizumab
- 76.9% vs 2.4%+74.5 vs placeboNCT03370133
10 other results
- 75.9% vs 1.2% NCT03410992
- 74% vs 3% NCT06011733
- 75% vs 0% NCT05020249
- 76.5% vs 31.4% NCT03412747
- 71% vs 47.3% NCT03536884
- 93% vs 4.8% NCT02905006
- 83.7% vs 4.8% NCT02905006
- 81.4% vs 4.8% NCT02905006
- 85% vs 4.8% NCT02905006
- 61.5% vs 4.8% NCT02905006
- sonelokimab
- 84.9% vs 90.6%vs SecukinumabNCT03384745
3 other results
- 90.2% vs 90.6% NCT03384745
- 88.5% vs 90.6% NCT03384745
- 65.4% vs 90.6% NCT03384745
PASI 90
- bimekizumab
- 85% vs 4.8%+80.2 vs placeboNCT03370133
48 other results
- 90.8% vs 1.2% NCT03410992
- 94% vs 3% NCT06011733
- 81.3% vs 0% NCT05020249
- 86.2% vs 47.2% NCT03412747
- 85% vs 2.4% NCT03370133
- 85.5% vs 74.3% NCT03536884
- 79.1% vs 0% NCT02905006
- 72.1% vs 0% NCT02905006
- 67.4% vs 0% NCT02905006
- 75% vs 0% NCT02905006
- 46.2% vs 0% NCT02905006
- 100% vs 81.1% NCT03010527
- 100% vs 67.6% NCT03010527
- 100% vs 83.8% NCT03010527
- 86% vs 0% NCT02905006
- 97% vs 45.9% NCT03010527
- 96.7% vs 81.1% NCT03010527
- 100% vs 67.6% NCT03010527
- 96.7% vs 83.8% NCT03010527
- 69.8% vs 0% NCT02905006
- 100% vs 45.9% NCT03010527
- 96.4% vs 81.1% NCT03010527
- 96.4% vs 67.6% NCT03010527
- 92.7% vs 83.8% NCT03010527
- 58.1% vs 0% NCT02905006
- 100% vs 45.9% NCT03010527
- 100% vs 81.1% NCT03010527
- 83.3% vs 67.6% NCT03010527
- 100% vs 83.8% NCT03010527
- 66.7% vs 45.9% NCT03010527
- 62.5% vs 81.1% NCT03010527
- 50% vs 67.6% NCT03010527
- 62.5% vs 83.8% NCT03010527
- 50% vs 45.9% NCT03010527
- 64.3% vs 81.1% NCT03010527
- 57.1% vs 67.6% NCT03010527
- 64.3% vs 83.8% NCT03010527
- 67.5% vs 0% NCT02905006
- 42.9% vs 45.9% NCT03010527
- 100% vs 81.1% NCT03010527
- 78.9% vs 81.1% NCT03010527
- 100% vs 67.6% NCT03010527
- 73.7% vs 67.6% NCT03010527
- 100% vs 83.8% NCT03010527
- 78.9% vs 83.8% NCT03010527
- 41% vs 0% NCT02905006
- 100% vs 45.9% NCT03010527
- 42.1% vs 45.9% NCT03010527
- sonelokimab
- 69.8% vs 64.2%vs SecukinumabNCT03384745
3 other results
- 76.5% vs 64.2% NCT03384745
- 65.4% vs 64.2% NCT03384745
- 36.5% vs 64.2% NCT03384745
PASI 100
- bimekizumab
- 61.7% vs 48.9%vs SecukinumabNCT03536884
10 other results
- 58.6% vs 0% NCT03370133
- 68.2% vs 1.2% NCT03410992
- 65% vs 0% NCT06011733
- 21.9% vs 0% NCT05020249
- 60.8% vs 23.9% NCT03412747
- 55.8% vs 0% NCT02905006
- 48.8% vs 0% NCT02905006
- 27.9% vs 0% NCT02905006
- 60% vs 0% NCT02905006
- 28.2% vs 0% NCT02905006
- sonelokimab
- 37.7% vs 28.3%vs SecukinumabNCT03384745
3 other results
- 33.3% vs 28.3% NCT03384745
- 25% vs 28.3% NCT03384745
- 17.3% vs 28.3% NCT03384745
sPGA 0/1
- bimekizumab
- 84.1% vs 4.8%+79.3 vs placeboNCT03370133
1 other result
- 81.9% vs 4.8% NCT03370133
- sonelokimab
- —Not reported
DLQI, change
- bimekizumab
- —Trial running · NCT06506916
- sonelokimab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. bimekizumab: 5 of 5 rows · sonelokimab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | bimekizumab Rows use multiple source trials | sonelokimab |
|---|---|---|
| IGA 0/1 responder rate · % of participants Induction | 85.3% (n=319) vs 57.2% (n=159) Adalimumab @ 16wk320 mg Q4W + 320 mg Q4W/Q8Wa,b,c,d NCT03412747 · Phase 3 · combination · Psoriasis · phase 3 4 other source trials92.6% (n=349) vs 1.2% (n=86) placebo @ 16wk320 mg Q4W NCT03410992 · Phase 3 92% (n=100) vs 3% (n=33) placebo @ 16wkDosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 85.5% (n=373) vs 78.6% (n=370) Secukinumab @ 16wk320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence 87.5% (n=32) vs 0% (n=15) placebo @ 16wk320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence | 88.2% (n=51) vs 0% (n=52) placebo @ 12wk*120 mge,a,b,c,d NCT03384745 · Phase 2 · converted to % from 45 Participants as posted show 3 more doses77.4% (n=53) vs 0% (n=52) placebo @ 12wk*120 mg NCT03384745 · Phase 2 · converted to % from 41 Participants as posted 84.6% (n=52) vs 0% (n=52) placebo @ 12wk*60 mg NCT03384745 · Phase 2 · converted to % from 44 Participants as posted 48.1% (n=52) vs 0% (n=52) placebo @ 12wk*30 mg NCT03384745 · Phase 2 · converted to % from 25 Participants as posted |
| Dropout rate | —320 mg Q4Wf NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 46 more results—320 mg Q4W NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 —320 mg Q4W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W/Q8W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 2 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 100%320 mg Q4W NCT03598790 · Phase 3 · registry result, not featured evidence 10.4%320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 15.1%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence · combination —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 0%320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 5%320/160 mg NCT04718896 · Phase 2 · registry result, not featured evidence 0%64/32 mg NCT04718896 · Phase 2 · registry result, not featured evidence — NCT03230292 · Phase 2 · registry result, not featured evidence —320 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —320 mg NCT03025542 · Phase 2 · registry result, not featured evidence —320 mg + PBO NCT03025542 · Phase 2 · registry result, not featured evidence · combination —320 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —480 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg w/ LD Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence | —120 mgg NCT03384745 · Phase 2 show 7 more results—120 mg NCT03384745 · Phase 2 5.7%120 mg NCT03384745 · Phase 2 3.9%120 mg NCT03384745 · Phase 2 —60 mg NCT03384745 · Phase 2 1.9%60 mg NCT03384745 · Phase 2 0%30 mg NCT03384745 · Phase 2 —30 mg NCT03384745 · Phase 2 |
| Discontinued due to AEs | —320 mg Q4Wf NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 46 more results—320 mg Q4W NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 —320 mg Q4W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W/Q8W NCT03412747 · Phase 3 · Psoriasis · phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q4W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —320 mg Q4W/Q8W NCT03410992 · Phase 3 —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 2 NCT06011733 · Phase 3 · registry result, not featured evidence · combination —Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 34.3%320 mg Q4W NCT03598790 · Phase 3 · registry result, not featured evidence 4%320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 6.3%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence · combination —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320 mg NCT03766685 · Phase 3 · registry result, not featured evidence —320/160 mg NCT04718896 · Phase 2 · registry result, not featured evidence —64/32 mg NCT04718896 · Phase 2 · registry result, not featured evidence — NCT03230292 · Phase 2 · registry result, not featured evidence —320 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence —320 mg NCT03025542 · Phase 2 · registry result, not featured evidence —320 mg + PBO NCT03025542 · Phase 2 · registry result, not featured evidence · combination —320 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —480 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —160 mg w/ LD Q4W NCT02905006 · Phase 2 · registry result, not featured evidence —64 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence | —120 mgg NCT03384745 · Phase 2 show 7 more results—120 mg NCT03384745 · Phase 2 1.9%120 mg NCT03384745 · Phase 2 3.9%120 mg NCT03384745 · Phase 2 —60 mg NCT03384745 · Phase 2 0%60 mg NCT03384745 · Phase 2 0%30 mg NCT03384745 · Phase 2 —30 mg NCT03384745 · Phase 2 |
| Serious AEs | 6.1%320 mg Q4Wf NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 46 more results1.6%320 mg Q4W NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 2.5%320 mg Q4W NCT03412747 · Phase 3 · Psoriasis · phase 3 0.6%320 mg Q4W/Q8W NCT03412747 · Phase 3 · Psoriasis · phase 3 1.7%320 mg Q4W NCT03410992 · Phase 3 0%320 mg Q4W NCT03410992 · Phase 3 4.7%320 mg Q4W/Q4W NCT03410992 · Phase 3 0%320 mg Q4W/Q4W NCT03410992 · Phase 3 3%320 mg Q4W/Q8W NCT03410992 · Phase 3 0%320 mg Q4W/Q8W NCT03410992 · Phase 3 3.1%Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence · combination 4.2%Dosage Regimen 2 NCT06011733 · Phase 3 · registry result, not featured evidence · combination 1%Dosage Regimen 1 NCT06011733 · Phase 3 · registry result, not featured evidence 7.2%320 mg Q4W NCT03598790 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 10.2%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 4.9%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 9.8%320 mg Q4W/Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 9.8%320 mg Q8W NCT03598790 · Phase 3 · registry result, not featured evidence 4%320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence · combination 2.7%320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q4W NCT03536884 · Phase 3 · registry result, not featured evidence —320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 4.2%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 3.7%320 mg Q4W NCT03536884 · Phase 3 · registry result, not featured evidence 8.9%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 11.1%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 1.5%320 mg Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 6.8%320 mg Q4W/Q8W NCT03536884 · Phase 3 · registry result, not featured evidence 0%320 mg Q4W NCT05020249 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 0%320 mg NCT03766685 · Phase 3 · registry result, not featured evidence 10%320/160 mg NCT04718896 · Phase 2 · registry result, not featured evidence 14.3%64/32 mg NCT04718896 · Phase 2 · registry result, not featured evidence 7% NCT03230292 · Phase 2 · registry result, not featured evidence 7.7%320 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence 6.3%160 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence 6.7%64 mg Q4W NCT03010527 · Phase 2 · registry result, not featured evidence 5.9%320 mg NCT03025542 · Phase 2 · registry result, not featured evidence 6.3%320 mg + PBO NCT03025542 · Phase 2 · registry result, not featured evidence · combination 0%320 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 2.3%480 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 0%160 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 0%160 mg w/ LD Q4W NCT02905006 · Phase 2 · registry result, not featured evidence 0%64 mg Q4W NCT02905006 · Phase 2 · registry result, not featured evidence | 2%120 mgg NCT03384745 · Phase 2 show 7 more results1.9%120 mg NCT03384745 · Phase 2 —120 mg NCT03384745 · Phase 2 —120 mg NCT03384745 · Phase 2 1.9%60 mg NCT03384745 · Phase 2 —60 mg NCT03384745 · Phase 2 —30 mg NCT03384745 · Phase 2 3.8%30 mg NCT03384745 · Phase 2 |
| Most frequent reported AEs | 320 mg Q4Wf nasopharyngitis 21.8% (placebo 8.4%) oral candidiasis 15.2% (placebo 0%) upper respiratory tract infection 9.1% (placebo 2.4%) NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 show 43 more results320 mg Q4W nasopharyngitis 9.3% (placebo 8.4%) oral candidiasis 8.7% (placebo 0%) headache 3.4% (placebo 0%) NCT03370133 · Phase 3 · monotherapy · Psoriasis, Psoriatic Arthritis · phase 3 320 mg Q4W nasopharyngitis 20.3% oral candidiasis 9.5% diarrhoea 5.1% NCT03412747 · Phase 3 · Psoriasis · phase 3 320 mg Q4W/Q8W nasopharyngitis 16.8% oral candidiasis 11.8% upper respiratory tract infection 7.5% NCT03412747 · Phase 3 · Psoriasis · phase 3 320 mg Q4W nasopharyngitis 6.6% (placebo 4.7%) oral candidiasis 6% (placebo 0%) upper respiratory tract infection 4% (placebo 8.1%) NCT03410992 · Phase 3 320 mg Q4W nasopharyngitis 4.3% (placebo 4.7%) neutropenia 4.3% (placebo 0%) oral candidiasis 4.3% (placebo 0%) NCT03410992 · Phase 3 320 mg Q4W/Q4W oral candidiasis 11.3% (placebo 0%) upper respiratory tract infection 11.3% (placebo 8.1%) nasopharyngitis 10.4% (placebo 4.7%) NCT03410992 · Phase 3 320 mg Q4W/Q4W body tinea 14.3% (placebo 0%) neutropenia 14.3% (placebo 0%) psoriasis 14.3% (placebo 4.7%) NCT03410992 · Phase 3 320 mg Q4W/Q8W nasopharyngitis 23% (placebo 4.7%) oral candidiasis 9% (placebo 0%) upper respiratory tract infection 8% (placebo 8.1%) NCT03410992 · Phase 3 320 mg Q4W/Q8W dental caries 25% (placebo 1.2%) impetigo 25% (placebo 1.2%) rib fracture 25% (placebo 0%) NCT03410992 · Phase 3 Dosage Regimen 1 upper respiratory tract infection 18.5% (placebo 6.1%) injection site pain 5.4% (placebo 3%) hyperlipidaemia 3.8% (placebo 6.1%) NCT06011733 · Phase 3 · registry result, not featured evidence · combination Dosage Regimen 2 hepatic function abnormal 7.3% (placebo 0%) eczema 5.2% (placebo 0%) latent tuberculosis 5.2% (placebo 0%) NCT06011733 · Phase 3 · registry result, not featured evidence · combination Dosage Regimen 1 upper respiratory tract infection 21% (placebo 6.1%) hyperlipidaemia 5% (placebo 6.1%) injection site pain 5% (placebo 3%) NCT06011733 · Phase 3 · registry result, not featured evidence 320 mg Q4W nasopharyngitis 19.3% oral candidiasis 16.1% upper respiratory tract infection 8.2% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 14.3% nasopharyngitis 12.5% oral candidiasis 10.4% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 15% nasopharyngitis 6.2% oral candidiasis 5.8% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q4W/Q8W corona virus infection 19.5% oral candidiasis 14.6% dermatitis contact 9.8% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 5.9% oral candidiasis 5.9% dermatitis contact 3.9% NCT03598790 · Phase 3 · registry result, not featured evidence 320 mg Q4W nasopharyngitis 16.6% oral candidiasis 13.4% upper respiratory tract infection 6.2% NCT03536884 · Phase 3 · registry result, not featured evidence · combination 320 mg Q4W nasopharyngitis 12.6% oral candidiasis 10.5% upper respiratory tract infection 4.3% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W oral candidiasis 16.7% nasopharyngitis 15.3% upper respiratory tract infection 9.8% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q4W oral candidiasis 13.3% nasopharyngitis 11.6% urinary tract infection 6.5% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W nasopharyngitis 9.9% oral candidiasis 8.5% corona virus infection 7.8% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 22.2% arthropod bite 11.1% basal cell carcinoma 11.1% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q8W corona virus infection 10.6% oral candidiasis 6.1% nasopharyngitis 4.5% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q4W/Q8W corona virus infection 16.9% oral candidiasis 8.5% basal cell carcinoma 3.4% NCT03536884 · Phase 3 · registry result, not featured evidence 320 mg Q4W corona virus infection 21.9% (placebo 6.7%) eczema 6.3% (placebo 0%) tinea pedis 6.3% (placebo 0%) NCT05020249 · Phase 3 · registry result, not featured evidence 320 mg injection site pain 0% injection site reaction 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320 mg injection site pain 5.3% injection site reaction 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320 mg injection site pain 0% injection site reaction 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320 mg injection site reaction 5.3% injection site pain 0% NCT03766685 · Phase 3 · registry result, not featured evidence 320/160 mg nasopharyngitis 45% urinary tract infection 25% alanine aminotransferase increased 10% NCT04718896 · Phase 2 · registry result, not featured evidence 64/32 mg nasopharyngitis 33.3% upper respiratory tract infection 23.8% pharyngitis 14.3% NCT04718896 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 18.6% nasopharyngitis 16.3% gamma-glutamyltransferase increased 11.6% NCT03230292 · Phase 2 · registry result, not featured evidence 320 mg Q4W oral candidiasis 16.5% nasopharyngitis 12.1% upper respiratory tract infection 9.9% NCT03010527 · Phase 2 · registry result, not featured evidence 160 mg Q4W nasopharyngitis 13.5% oral candidiasis 11.7% upper respiratory tract infection 9% NCT03010527 · Phase 2 · registry result, not featured evidence 64 mg Q4W hypertension 13.3% nasopharyngitis 13.3% psoriasis 13.3% NCT03010527 · Phase 2 · registry result, not featured evidence 320 mg nasopharyngitis 23.5% alanine aminotransferase increased 17.6% gamma-glutamyltransferase increased 17.6% NCT03025542 · Phase 2 · registry result, not featured evidence 320 mg + PBO upper respiratory tract infection 18.8% hyperkalaemia 12.5% urinary tract infection 12.5% NCT03025542 · Phase 2 · registry result, not featured evidence · combination 320 mg Q4W nasopharyngitis 14% (placebo 4.8%) oral candidiasis 7% (placebo 0%) neutropenia 4.7% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence 480 mg Q4W nasopharyngitis 9.3% (placebo 4.8%) arthralgia 7% (placebo 0%) headache 2.3% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence 160 mg Q4W gamma-glutamyltransferase increased 7% (placebo 2.4%) nasopharyngitis 7% (placebo 4.8%) tonsillitis 4.7% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence 160 mg w/ LD Q4W nasopharyngitis 7.5% (placebo 4.8%) upper respiratory tract infection 7.5% (placebo 2.4%) gamma-glutamyltransferase increased 5% (placebo 2.4%) NCT02905006 · Phase 2 · registry result, not featured evidence 64 mg Q4W nasopharyngitis 12.8% (placebo 4.8%) upper respiratory tract infection 12.8% (placebo 2.4%) arthralgia 5.1% (placebo 0%) NCT02905006 · Phase 2 · registry result, not featured evidence | 120 mgg nasopharyngitis 7.8% (placebo 7.7%) pruritus 7.8% (placebo 3.8%) oral candidiasis 5.9% (placebo 0%) NCT03384745 · Phase 2 show 3 more results120 mg nasopharyngitis 17% (placebo 7.7%) headache 5.7% (placebo 1.9%) pruritus 5.7% (placebo 3.8%) NCT03384745 · Phase 2 60 mg nasopharyngitis 21.2% (placebo 7.7%) pruritus 7.7% (placebo 3.8%) headache 5.8% (placebo 1.9%) NCT03384745 · Phase 2 30 mg nasopharyngitis 7.7% (placebo 7.7%) arthralgia 5.8% (placebo 1.9%) hypertension 5.8% (placebo 3.8%) NCT03384745 · Phase 2 |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 16 weeks versus 12 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for 43 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
bimekizumab
show 2 more results
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 21 more results
show 6 more results
show 14 more results
+ 41 further endpoints in the CSV export.
Hidradenitis Suppurativa
Shared mechanism: IL-17A/F · full Hidradenitis Suppurativa pipeline
bimekizumab · Bimzelx
Marketed by UCB
NCT04242446 · Phase 3 · completed
This phase 3 trial randomised 505 adults with moderate to severe hidradenitis suppurativa to one of two bimekizumab regimens or placebo, with participants, care providers, investigators and outcome assessors all masked. The primary endpoint was HiSCR50 response at week 16. Regimen 2 exceeded placebo (47.8% vs 28.7%, p=0.006); for regimen 1 (45.3% vs 28.7%, p=0.030) the 97.5% confidence interval for the odds ratio included 1, and the record states that the testing hierarchy failed on this endpoint. The record reports no power calculation or planned enrolment.
Next expected readout: December 2026 · NCT06921850 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16: HiSCR50 at week 16: bimekizumab dosing regimen 1 53.8% (n=144) and regimen 2 52.0% (n=291) vs placebo 32.2% (n=74); odds ratios 2.42 (95% CI 1.22 to 4.80), p=0.004, and 2.29 (95% CI 1.22 to 4.29), p=0.003 (CT.gov posted results). (met)
Result source: NCT04242498
sonelokimab
Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07007637 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hidradenitis Suppurativa
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
sonelokimab: no structured comparison results are available for Hidradenitis Suppurativa.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Psoriatic Arthritis
Shared mechanism: IL-17A/F · full Psoriatic Arthritis pipeline
bimekizumab · Bimzelx
Marketed by UCB
NCT03370133 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled phase 3 trial involving 567 participants. Both prespecified clinical skin endpoints at week 16—PASI90 and Investigator’s Global Assessment response—were significantly better with bimekizumab than with placebo and ustekinumab (all p<0.001).
Next expected readout: March 2027 · NCT06506916 (registry estimate)
Reported efficacy
Percentage of Participants With American College of Rheumatology 50 (ACR50) Response (From Baseline to Week 16): ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). (met)
Result source: NCT03896581
sonelokimab
Developed by MoonLake Immunotherapeutics under a licence from Merck KGaA
NCT06641076 · Phase 3 · active, not recruiting
This was a randomized, triple-masked Phase 3 trial with 960 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-08-10. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: January 2027 · NCT06641089 (registry estimate)
Reported efficacy
Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50) (Week 16): Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). (met)
Result source: NCT06641076
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | bimekizumab | sonelokimab |
|---|---|---|
| ACR20 | 62.2% vs 23.8%+38.4 vs placeboNCT038952035 other results
| —Trial running · NCT07223138 |
| ACR50 | 43.9% vs 10%+33.9 vs placeboNCT038952036 other results
| —Trial running · NCT07223138 |
| PASI 75 | 68.8% vs 10%+58.8 vs placeboNCT029695253 other results
| —Trial running · NCT07223138 |
| Minimal disease activity | 45% vs 13.2%+31.8 vs placeboNCT038952031 other result
| —Trial running · NCT07223138 |
| HAQ-DI, change | -0.3 vs -0.1−0.2 vs placeboNCT038952031 other result
| —Trial running · NCT07223138 |
ACR20
- bimekizumab
- 62.2% vs 23.8%+38.4 vs placeboNCT03895203
5 other results
- 67% vs 15.8% NCT03896581
- 73.2% vs 19% NCT02969525
- 61% vs 19% NCT02969525
- 51.2% vs 19% NCT02969525
- 53.7% vs 19% NCT02969525
- sonelokimab
- —Trial running · NCT07223138
ACR50
- bimekizumab
- 43.9% vs 10%+33.9 vs placeboNCT03895203
6 other results
- 43.4% vs 6.8% NCT03896581
- 41.5% vs 7.1% NCT02969525
- 46.3% vs 7.1% NCT02969525
- 24.4% vs 7.1% NCT02969525
- 26.8% vs 7.1% NCT02969525
- 49.1% vs 38.4% NCT06624228
- sonelokimab
- —Trial running · NCT07223138
PASI 75
- bimekizumab
- 68.8% vs 10%+58.8 vs placeboNCT02969525
3 other results
- 70.6% vs 10% NCT02969525
- 72.7% vs 10% NCT02969525
- 57.1% vs 10% NCT02969525
- sonelokimab
- —Trial running · NCT07223138
Minimal disease activity
- bimekizumab
- 45% vs 13.2%+31.8 vs placeboNCT03895203
1 other result
- 44.2% vs 6% NCT03896581
- sonelokimab
- —Trial running · NCT07223138
HAQ-DI, change
- bimekizumab
- -0.3 vs -0.1−0.2 vs placeboNCT03895203
1 other result
- -0.4 vs -0.1 NCT03896581
- sonelokimab
- —Trial running · NCT07223138
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. bimekizumab: 4 of 4 rows · sonelokimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | bimekizumab |
|---|---|
| Dropout rate | 3.7%160 mg Q4Wa NCT03895203 · Phase 3 show 8 more results—160 mg Q4W NCT03895203 · Phase 3 1.5%160 mg NCT03896581 · Phase 3 0%160 mg Q4W NCT04109976 · Phase 3 · registry result, not featured evidence 0.9%160 mg Q4W NCT04109976 · Phase 3 · registry result, not featured evidence —160 mg NCT03347110 · Phase 2 · registry result, not featured evidence —160 mg & 160 mg LD NCT02969525 · Phase 2 · registry result, not featured evidence —320 mg NCT02969525 · Phase 2 · registry result, not featured evidence —16 mg NCT02969525 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.9%160 mg Q4Wa NCT03895203 · Phase 3 show 8 more results—160 mg Q4W NCT03895203 · Phase 3 0.7%160 mg NCT03896581 · Phase 3 —160 mg Q4W NCT04109976 · Phase 3 · registry result, not featured evidence —160 mg Q4W NCT04109976 · Phase 3 · registry result, not featured evidence —160 mg NCT03347110 · Phase 2 · registry result, not featured evidence —160 mg & 160 mg LD NCT02969525 · Phase 2 · registry result, not featured evidence —320 mg NCT02969525 · Phase 2 · registry result, not featured evidence —16 mg NCT02969525 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.9%160 mg Q4Wa NCT03895203 · Phase 3 show 8 more results5.6%160 mg Q4W NCT03895203 · Phase 3 1.9%160 mg NCT03896581 · Phase 3 0%160 mg Q4W NCT04109976 · Phase 3 · registry result, not featured evidence 0%160 mg Q4W NCT04109976 · Phase 3 · registry result, not featured evidence 7.7%160 mg NCT03347110 · Phase 2 · registry result, not featured evidence 6.3%160 mg & 160 mg LD NCT02969525 · Phase 2 · registry result, not featured evidence 0%320 mg NCT02969525 · Phase 2 · registry result, not featured evidence 0%16 mg NCT02969525 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 160 mg Q4Wa nasopharyngitis 9.3% (placebo 4.6%) upper respiratory tract infection 5.1% (placebo 6.4%) oral candidiasis 2.1% (placebo 0%) NCT03895203 · Phase 3 show 6 more results160 mg Q4W nasopharyngitis 7% (placebo 4.6%) upper respiratory tract infection 4.8% (placebo 6.4%) urinary tract infection 4.8% (placebo 1.4%) NCT03895203 · Phase 3 160 mg nasopharyngitis 3.7% (placebo 0.8%) oral candidiasis 2.6% (placebo 0%) upper respiratory tract infection 2.2% (placebo 1.5%) NCT03896581 · Phase 3 160 mg upper respiratory tract infection 10.9% nasopharyngitis 10.4% psoriasis 7.7% NCT03347110 · Phase 2 · registry result, not featured evidence 160 mg & 160 mg LD nasopharyngitis 9.5% (placebo 0%) upper respiratory tract infection 9.5% (placebo 0%) respiratory tract infection 6.3% (placebo 0%) NCT02969525 · Phase 2 · registry result, not featured evidence 320 mg nasopharyngitis 13.8% (placebo 0%) upper respiratory tract infection 10% (placebo 0%) pharyngitis 8.8% (placebo 0%) NCT02969525 · Phase 2 · registry result, not featured evidence 16 mg nasopharyngitis 7.7% (placebo 0%) ear infection 5.1% (placebo 0%) insomnia 5.1% (placebo 0%) NCT02969525 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
bimekizumab
show 6 more results
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 5 more results
show 3 more results
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bimekizumab's landscape · sonelokimab's landscape